— Know what they know.
Not Investment Advice

DNAG OTC

DNAPrint Genomics, Inc.
1W: +0.0% 1M: +0.0% 3M: +0.0% YTD: +100.0% 1Y: +100.0% 3Y: -80.0% 5Y: +100.0%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Biotechnology · Tech Score Neutral · Power 50 · $12892 mcap · 413M float · 0.079% daily turnover

Balance Sheet Trends

Total Assets
$10M +62.7% ▲
5Y CAGR: +61.4%
Total Liabilities
$14M +34.4% ▲
5Y CAGR: +98.6%
Shareholders Equity
-$4M +9.3% ▲
Cash & Investments
$8M +370.4% ▲
5Y CAGR: +187.9%
Total Debt
$7M +580.7% ▲
5Y CAGR: +103.0%
Net Debt
$7M +1007.9% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2002FY2003FY2004FY2005FY2006
— Assets —
Cash$12K$266K$979K$2M$595K
Short-Term Investments$0$0$0$0$8M
Cash & ST Investments$12K$266K$979K$2M$8M
Net Receivables$10K$432K$237K$102K$75K
Inventory$0$0$65K$299K$96K
Other Current Assets$0$220K$0$118K$61K
Total Current Assets$35K$1M$1M$2M$9M
Property, Plant & Equip.$383K$282K$380K$1M$1M
Goodwill & Intangibles$0$0$0$326K$225K
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$5K$5K$5K$2M$23K
Total Non-Current Assets$388K$287K$385K$4M$1M
Total Assets$423K$1M$2M$6M$10M
— Liabilities —
Accounts Payable$660K$583K$353K$1M$3M
Short-Term Debt$868K$358K$504K$771K$7M
Deferred Revenue$0$62K$42K$195K$178K
Other Current Liabilities$0$0$0$7M$202K
Total Current Liabilities$2M$3M$2M$10M$14M
Long-Term Debt$0$470K$29K$126K$175K
Other Non-Current Liab.$0$308K$0$53K$0
Total Non-Current Liabilities$0$783K$124K$352K$206K
Total Liabilities$2M$3M$2M$10M$14M
— Equity —
Common Stock$5M$5M$9M$2M$5M
Retained Earnings-$9M-$17M-$28M-$37M-$46M
Accumulated OCI-$8M-$7M$323K$25K$6M
Total Stockholders Equity-$1M-$2M$96K-$4M-$4M
Total Liabilities & Equity$423K$1M$2M$6M$10M
— Key Metrics —
Total Debt$868K$833K$628K$1M$7M
Net Debt$856K$567K-$350K-$737K$7M
Total Investments$0$0$0$0$8M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms